A joint study by scientists at Stony Brook University, published in the journal Nature Communications, showed that decreased KRAS activity leads to a more favorable immune environment for fighting cancer, according to News-Medical..

“Our study shows that oncogenic KRAS plays a profound immunosuppressive role in maintaining cancer, and that cancer treatment will be improved by simultaneously inhibiting KRAS and activating immune pathways suppressed by cancer,” said Alexey Petrenko, Ph.D.. KRAS-deficient cells retain tumor-forming ability in immunodeficient mice. However, they cannot escape the immune system in immunocompetent wild-type mice, inducing a strong anti-tumor response.

“A key insight into the findings of this article is that mutations in KRAS not only promote tumor growth, but also keep tumors cool rather than hot when cytokine T cells attack cancer cells,” says co-author Scott Powers, professor. - We believe this study clearly demonstrates the ability of oncogenic KRAS to disrupt our anti-tumor immune responses. This highlights the need to develop therapeutic interventions that not only target the KRAS pathway, but also engage the immune defenses of cells. "

med-heal. ru.